Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences (NASDAQ: PCRX) announced its participation in two upcoming healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences (NASDAQ: PCRX) announced its participation in two upcoming healthcare conferences. The company will engage in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 19th at 3:00 PM GMT (10:00 AM ET).
Additionally, Pacira BioSciences will be present at the 36th Annual Piper Sandler Healthcare Conference on December 3rd at 1:00 PM ET. Interested parties can access live audio of these events on the “Events” page of the company’s website at investor.pacira.com. Replays will be available for two weeks following the events.
Details
News Market Reaction – PCRX
The recorded move for PCRX in the trading session of this news was -4.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
- Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).
- 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
About Pacira
Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.